In a randomised, double‑blind trial of single subanaesthetic infusions of racemic ketamine or esketamine in 61 people with treatment‑resistant major depressive disorder, higher baseline illness severity and a greater number of prior treatment failures predicted poorer outcomes. Specifically, more treatment failures and greater severity were associated with lower odds of remission at 7 days and reduced likelihood of response at 24 hours.
- Published
- Journal
- Human Psychopharmacology
- Authors
- Jesus‐Nunes, A. P., Leal, G. C., Correia‐Melo, F. S., Vieira, F., Mello, R. P., Caliman‐Fontes, A. T., Echegaray, M. V. F., Marback, R. F., Guerreiro‐Costa, L. N. F., Souza‐Marques, B., Santos‐Lima, C., Souza, L. S., Bandeira, I. D., Kapczinski, F., Lacerda, A. L. T., Quarantini, L. C.